252 related articles for article (PubMed ID: 34515661)
1. A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy.
Pacak K; Kidd M; Meuter L; Modlin IM
Endocr Relat Cancer; 2021 Oct; 28(11):731-744. PubMed ID: 34515661
[TBL] [Abstract][Full Text] [Related]
2. The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.
Pęczkowska M; Cwikla J; Kidd M; Lewczuk A; Kolasinska-Ćwikła A; Niec D; Michałowska I; Prejbisz A; Januszewicz A; Chiarelli J; Bodei L; Modlin I
Eur J Endocrinol; 2017 Feb; 176(2):143-157. PubMed ID: 27913608
[TBL] [Abstract][Full Text] [Related]
3. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
Shankavaram U; Fliedner SM; Elkahloun AG; Barb JJ; Munson PJ; Huynh TT; Matro JC; Turkova H; Linehan WM; Timmers HJ; Tischler AS; Powers JF; de Krijger R; Baysal BE; Takacova M; Pastorekova S; Gius D; Lehnert H; Camphausen K; Pacak K
Neoplasia; 2013 Apr; 15(4):435-47. PubMed ID: 23555188
[TBL] [Abstract][Full Text] [Related]
4. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
Vicha A; Musil Z; Pacak K
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
[TBL] [Abstract][Full Text] [Related]
5. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
6. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.
Fliedner SM; Kaludercic N; Jiang XS; Hansikova H; Hajkova Z; Sladkova J; Limpuangthip A; Backlund PS; Wesley R; Martiniova L; Jochmanova I; Lendvai NK; Breza J; Yergey AL; Paolocci N; Tischler AS; Zeman J; Porter FD; Lehnert H; Pacak K
PLoS One; 2012; 7(7):e40949. PubMed ID: 22859959
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A in a Cohort of Pheochromocytomas and Paragangliomas: Usefulness at Diagnosis and as an Early Biomarker of Recurrence.
Parisien-La Salle S; Provençal M; Bourdeau I
Endocr Pract; 2021 Apr; 27(4):318-325. PubMed ID: 33581325
[TBL] [Abstract][Full Text] [Related]
8. Hereditary pheochromocytoma and paraganglioma.
Mazzaglia PJ
J Surg Oncol; 2012 Oct; 106(5):580-5. PubMed ID: 22648936
[TBL] [Abstract][Full Text] [Related]
9. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
Jochmanová I; Yang C; Zhuang Z; Pacak K
J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
[TBL] [Abstract][Full Text] [Related]
11. Genomic Landscape of Pheochromocytoma and Paraganglioma.
Jochmanova I; Pacak K
Trends Cancer; 2018 Jan; 4(1):6-9. PubMed ID: 29413423
[TBL] [Abstract][Full Text] [Related]
12. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and management of metastatic pheochromocytoma and paraganglioma].
Jochmanová I; Lazúrová I
Vnitr Lek; 2017; 63(9):580-588. PubMed ID: 29120654
[TBL] [Abstract][Full Text] [Related]
14. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
16. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma and paraganglioma.
Pacak K; Wimalawansa SJ
Endocr Pract; 2015 Apr; 21(4):406-12. PubMed ID: 25716634
[TBL] [Abstract][Full Text] [Related]
18. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
[TBL] [Abstract][Full Text] [Related]
19. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors.
Jochmanová I; Zelinka T; Widimský J; Pacak K
Physiol Res; 2014; 63(Suppl 2):S251-62. PubMed ID: 24908231
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
